- Home
- AREB vs PALI Comparison
AREB vs PALI Comparison
Compare AREB & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AREB
- PALI
- Stock Information
- Founded
- AREB 2014
- PALI 1996
- Country
- AREB United States
- PALI United States
- Employees
- AREB N/A
- PALI N/A
- Industry
- AREB Plastic Products
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AREB Industrials
- PALI Health Care
- Exchange
- AREB Nasdaq
- PALI Nasdaq
- Market Cap
- AREB 2.8M
- PALI 3.4M
- IPO Year
- AREB N/A
- PALI N/A
- Fundamental
- Price
- AREB $0.87
- PALI $0.94
- Analyst Decision
- AREB
- PALI Strong Buy
- Analyst Count
- AREB 0
- PALI 2
- Target Price
- AREB N/A
- PALI $23.00
- AVG Volume (30 Days)
- AREB 139.9K
- PALI 192.2K
- Earning Date
- AREB 02-07-2025
- PALI 03-25-2025
- Dividend Yield
- AREB N/A
- PALI N/A
- EPS Growth
- AREB N/A
- PALI N/A
- EPS
- AREB N/A
- PALI N/A
- Revenue
- AREB $14,447,104.00
- PALI N/A
- Revenue This Year
- AREB $45.19
- PALI N/A
- Revenue Next Year
- AREB N/A
- PALI N/A
- P/E Ratio
- AREB N/A
- PALI N/A
- Revenue Growth
- AREB N/A
- PALI N/A
- 52 Week Low
- AREB $0.85
- PALI $0.89
- 52 Week High
- AREB $9.27
- PALI $9.65
- Technical
- Relative Strength Index (RSI)
- AREB 25.16
- PALI 24.22
- Support Level
- AREB $0.85
- PALI $0.95
- Resistance Level
- AREB $1.14
- PALI $1.08
- Average True Range (ATR)
- AREB 0.11
- PALI 0.09
- MACD
- AREB -0.01
- PALI -0.01
- Stochastic Oscillator
- AREB 4.08
- PALI 10.43
About AREB American Rebel Holdings Inc.
American Rebel Holdings Inc develops self-defense, safe storage, and patriotic products. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, vault doors, and Others.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.